Welcome, Guest |
TOPIC:
Zepatier - PBAC yes for GT1 but no for GT3 7 years 8 months ago #20968
The Pharmaceutical Benefits Advisory Committee (PBAC) has agreed there is a need for interferon-free treatment regimens for people with hepatitis C – genotypes 4 and 6. At its July meeting PBAC recommended that the combination of grazoprevir + elbasvir (Zepatier®) be listed on the Pharmaceutical Benefits Scheme (PBS). It was also recommended as a further option for people with genotype 1. Merck Sharpe and Dohme, who produce the medicine, also sought PBS listing for genotype 3 but PBAC considered there was insufficient data to support use with genotype 3 at this time. [which is a damn pity because Canada disagrees] YMMV | |
Zepatier - PBAC yes for GT1 but no for GT3 7 years 8 months ago #20974
That is wonderful news for genotypes 4 and 6 including G1's but it seems so very unfair for those with G3. Where is the dislike tab? gt 1a VL 6m F2/3 FibroScan - 9KPa in 2011 and 7KPa in 2015 sof/dac 10 December for 12 weeks pre tx alt 85 ast 51 4 wk alt 34 ast 31 UND <35 8 wk alt 29 ast 32 UND <15 12wk alt 25 ast 25 EOT 3.3.16 SVR24 UND KPa5.3 F0 in normal range I am well .forever grateful to fixhepc | |
Zepatier - PBAC yes for GT1 but no for GT3 7 years 7 months ago #21260
| Maybe it's possible that Zepatier could interfere with the PBAC's deal with Gilead and funding caps given that G3 is more prevelant here. Two time relapser. SVR 4 achieved 12/16 at last SVR 12 achieved 22/02/2017 The Bastard has been defeated GT 3 - about 28 yrs with HCV The following user(s) said Thank You: Donna |
Time to create page: 0.064 seconds